From MarketBeat:



Hikma Pharmaceuticals PLC has received an overall “Moderate Buy” rating from six research firms. Among these firms, three have rated the stock as a hold, while the remaining three have issued a buy rating. The average 1-year target price for the stock is GBX 1,972.50 ($25.06). Various brokerages have also released their reports on the company, with Citigroup, Royal Bank of Canada, and JPMorgan Chase & Co. restating their “buy” and “overweight” ratings on Hikma Pharmaceuticals.

The stock of Hikma Pharmaceuticals opened at GBX 1,773 on Tuesday and has a market cap of £3.92 billion. It also has a 12-month low of GBX 1,535 and a high of GBX 2,222. The company operates in three segments: Injectables, Generics, and Branded. MarketBeat’s editorial team reviewed this story before publication.

If you are considering Hikma Pharmaceuticals for investment, MarketBeat suggests looking into other top-rated stocks recommended by analysts, as Hikma Pharmaceuticals did not make it to their list of suggested buys.



Read more: Hikma Pharmaceuticals PLC (LON:HIK) Given Average Rating of “Moderate Buy” by Brokerages